Krystal Biotech: The Skin-Deep Gene Therapy Anomaly - $KRYS

Podcast: Empor.top - The Stories of Top Companies · Empor.top

Opublikowano: 2026-10-07

While the gene therapy industry spent a decade burning billions on one-time intravenous cures, Krystal Biotech quietly engineered a radical counter-strategy: putting a redosable genetic medicine into a topical gel, building commercial factories before pivotal data, and steering clear of venture capital. Today, that gamble has yielded VYJUVEK—a commercial rare-disease therapy generating software-like 95% gross margins, eleven consecutive profitable quarters, and a $1 billion cash cushion. Yet as U.S. market saturation and intermittent patient utilization begin to temper domestic growth, Krystal faces a pivotal strategic test: proving whether its unfashionable herpes-virus vector is a true multi-indication platform capable of co...